News
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....
Why bluebird bio Inc. Jumped Higher Today
Shares of biotech bluebird bio (NASDAQ: BLUE) are up 7.3% at 12:24 p.m. EDT, having been up as much as 16.3% today, after the company disclosed data in its abstracts for the American Society of....
3 Worst Performing Stocks in October
Halloween has come and gone, but some stocks have been more tricks than treats. As good as October may have been for a lot of investors, some stocks got totally crushed last month.Trivago (NASDAQ:....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Up in Smoke: This Marijuana Stock Imploded Last Week
Few industries have put a wider smile on investors' faces this year than marijuana. As recently as June, the average marijuana stock was higher by more than 330% over the trailing 12-month period,....
If I Could Buy Only 1 Stock, This Would Be It
What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.Second, I like dividends. The....
If I Could Buy Only 1 Stock, This Would Be It
What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.Second, I like dividends. The....
Masimo Corporation's Mighty Momentum Continues in 3rd Quarter
Things looked so great for Masimo Corporation (NASDAQ: MASI) when it reported results from the second quarter in August that the company upped its full-year guidance. Revenue and earnings soared,....
The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%
Shares of Stemline Therapeutics (NASDAQ: STML), a small-cap clinical-stage biotechnology company with a focus on developing medicines to treat cancer, skyrocketed as much as 33% during Tuesday's....
BASTIDE : Honoraires des controleurs légaux (exercice clos au 30 juin 2017)
MONTANT DES HONORAIRES DES COMMISSAIRES AUX COMPTES
VERSES AU 30 JUIN 2017
Conformément à l'article 221-1-2 du Règlement général de l'Autorité des Marchés financiers
En euros hors....
Ionis Down Big on Analyst Miss
This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize,....
Ionis Down Big on Analyst Miss
This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize,....
Ionis Down Big on Analyst Miss
This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize,....
Why Endo International plc Jumped and Then Faded -- Twice
Endo International (NASDAQ: ENDP) was up as much as 13.6% Tuesday before settling down to about half that gain after reporting preliminary third-quarter revenue and earnings results on Monday. The....
BASTIDE : Communiqué de mise à disposition du rapport financier annuel (Exercice clos au 30 juin 2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Communiqué de....
Why Novavax Stock Is Soaring Today
Shares of flu vaccine researcher Novavax (NASDAQ: NVAX) shot up 13.7% in early trading Tuesday after a positive analyst note out of Citigroup predicted "strong market opportunities" for the....
Why Exact Sciences Shares Are Soaring 11.6% Today
After the company reported better-than-expected top- and bottom-line third-quarter results today, shares of Exact Sciences (NASDAQ: EXAS) are jumping 11.6% at 12:30 p.m. EDT.As many as 20 million....
Why Geron Corporation Stock Is Jumping Today
Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by as much as 13.5% in early morning trading today, thanks to a Fast Track designation from the U.S. Food and Drug....
Why Geron Corporation Stock Is Jumping Today
Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by as much as 13.5% in early morning trading today, thanks to a Fast Track designation from the U.S. Food and Drug....
Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE: PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half as much as the S&P 500 index. Although Pfizer....
Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE: PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half as much as the S&P 500 index. Although Pfizer....
Exact Sciences' Earnings Hammer Short-Sellers (Again)
Americans have historically done poorly when it comes to sticking to recommended guidelines for colon cancer screening, but a new test launched by Exact Sciences (NASDAQ: EXAS) may be changing....
If Celgene Buys This Biotech, Investors Should Win Big-Time
Celgene (NASDAQ: CELG) has fallen on hard times of late -- or its stock has, at least. At the beginning of October, the biotech's share price was up 25% year to date. By the end of the month,....